Article (Scientific journals)
Cabergoline for Cushing's disease: a large retrospective multicenter study.
Ferriere, A.; Cortet, C.; Chanson, P. et al.
2017In European Journal of Endocrinology, 176 (3), p. 305-314
Peer Reviewed verified by ORBi
 

Files


Full Text
EuropeanJournalofEndo-Ferriere2017.pdf
Publisher postprint (1.42 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] OBJECTIVE: The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of patients with CD. DESIGN: We conducted a retrospective multicenter study from thirteen French and Belgian university hospitals. METHODS: Sixty-two patients with CD received cabergoline monotherapy or add-on therapy. Symptom score, biological markers of hypercortisolism and adverse effects were recorded. RESULTS: Twenty-one (40%) of 53 patients who received cabergoline monotherapy had normal urinary free cortisol (UFC) values within 12 months (complete responders), and five of these patients developed corticotropic insufficiency. The fall in UFC was associated with significant reductions in midnight cortisol and plasma ACTH, and with clinical improvement. Compared to other patients, complete responders had similar median baseline UFC (2.0 vs 2.5xULN) and plasma prolactin concentrations but received lower doses of cabergoline (1.5 vs 3.5 mg/week, P < 0.05). During long-term treatment (>12 months), cabergoline was withdrawn in 28% of complete responders because of treatment escape or intolerance. Overall, sustained control of hypercortisolism was obtained in 23% of patients for 32.5 months (19-105). Nine patients on steroidogenesis inhibitors received cabergoline add-on therapy for 19 months (1-240). Hypercortisolism was controlled in 56% of these patients during the first year of treatment with cabergoline at 1.0 mg/week (0.5-3.5). CONCLUSIONS: About 20-25% of CD patients are good responders to cabergoline therapy allowing long-term control of hypercortisolism at relatively low dosages and with acceptable tolerability. No single parameter, including the baseline UFC and prolactin levels, predicted the response to cabergoline.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Ferriere, A.
Cortet, C.
Chanson, P.
Delemer, B.
Caron, P.
Chabre, O.
Reznik, Y.
Bertherat, J.
Rohmer, V.
Briet, C.
Raingeard, I.
Castinetti, F.
Beckers, Albert ;  Université de Liège > Département des sciences cliniques > Endocrinologie
VROONEN, Laurent ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'endocrinologie clinique
Maiter, D.
Cephise-Velayoudom, F. L.
Nunes, M. L.
Haissaguerre, M.
Tabarin, A.
More authors (9 more) Less
Language :
English
Title :
Cabergoline for Cushing's disease: a large retrospective multicenter study.
Publication date :
2017
Journal title :
European Journal of Endocrinology
ISSN :
0804-4643
eISSN :
1479-683X
Publisher :
BioScientifica, United Kingdom
Volume :
176
Issue :
3
Pages :
305-314
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
(c) 2017 European Society of Endocrinology.
Available on ORBi :
since 19 January 2017

Statistics


Number of views
88 (6 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
68
Scopus citations®
without self-citations
58
OpenCitations
 
51

Bibliography


Similar publications



Contact ORBi